.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
UBS
Covington
AstraZeneca
Healthtrust
Citi
Teva
US Army
Moodys
Cipla

Generated: December 18, 2017

DrugPatentWatch Database Preview

Details for Patent: 5,860,946

« Back to Dashboard

Which drugs does patent 5,860,946 protect, and when does it expire?


Patent 5,860,946 protects VAGIFEM and is included in one NDA. There has been one Paragraph IV challenge on Vagifem.

This patent has six patent family members in six countries.

Summary for Patent: 5,860,946

Title: Instrument for inserting a suppository
Abstract:In an instrument for inserting a suppository, which instrument comprises a tubular housing (31) with a first end adapted to receive said suppository between two tongues (30) and a second end through which a plunger (22) is inserted in the tube, which plunger has a first end having a circular cross section and two axially spaced circumferential flanges (26, 27) and a second end projecting from the second end of the tube (31). The first end of the tube has an inwardly extending shoulder (25) which engage between said flanges (26, 27) and the first end of the piston is by radial slots divided into an uneven number of sectors (29). The plunger (22) has between its first end and a press button (24) at its second end angular spaced radial walls (21) abutting the inner wall of the tube (31) and axial spaced disc shaped walls are provided having a diameter corresponding to the inner diameter of the tube (31).
Inventor(s): Hofstatter; Thibaud (Helsing.o slashed.r, DK)
Assignee: Novo Nordisk A/S (Bagsvaerd, DK)
Application Number:08/886,588
Patent Claim Types:
see list of patent claims
Dosage form;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Novo Nordisk IncVAGIFEMestradiolTABLET;VAGINAL020908-002Nov 25, 2009ABRXYesYes► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 5,860,946

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Denmark0752/96Jul 05, 1996

International Patent Family for Patent: 5,860,946

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria240764► Subscribe
Australia3254397► Subscribe
Canada2258310► Subscribe
Germany69722203► Subscribe
European Patent Office0910427► Subscribe
World Intellectual Property Organization (WIPO)9801180► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Citi
AstraZeneca
Covington
Teva
Cipla
Chubb
Moodys
QuintilesIMS
Federal Trade Commission
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot